A Study of XSTEM-VLU in Patients With Difficult-to-heal Venous Leg Ulcers

Last updated: April 30, 2025
Sponsor: Xintela AB
Overall Status: Active - Recruiting

Phase

1/2

Condition

Venous Leg Ulcers

Stasis Dermatitis

Ulcers

Treatment

XSTEM-VLU

Vehicle

Clinical Study ID

NCT05549609
XIN-XSTEM-201
  • Ages > 18
  • All Genders

Study Summary

The aim of the study is to assess safety, tolerability and preliminary efficacy of XSTEM-VLU when administered as a single topical dose to patients with difficult-to-heal venous leg ulcers. The study is randomised and the patients will receive either XSTEM-VLU or vehicle as add on to standard wound care.

The patients will be followed weekly for 10 weeks after treatment. At 4 months after treatment, the patients will return to the clinic for an end-of-study visit.

Eligibility Criteria

Inclusion

Major Inclusion Criteria:

  • Written informed consent for participation in the study

  • Male or female patient aged ≥18 years

  • BMI ≥18.5 and ≥40.0 kg/m2

  • Lower leg wound due to venous insufficiency

  • Target wound has failed to heal despite standard wound care for a minimum of 6 weeks

  • A surface area of the target wound of ≥2 and ≤40 cm2

Exclusion

Major Exclusion Criteria:

  • Signs or symptoms of clinically significant ongoing infection i the target woundrequiring anti-microbial treatment

  • History of autoimmune disease, such as but not limited to systemic lupuserythematosus, Addison's disease, Crohn's disease and type I diabetes mellitus

  • B-HbA1C value ≥52 mmol/mol

  • Plaque psoriasis or any other skin disease that could interfere with the outcome ofthe study

  • Arterial insufficiency

  • History of any malignancy within the past 5 years

  • Target wound diagnosed as a malignant wound, neuropathic wound, pressure wound orosteomyelitis

  • Patients who are immunocompromised due to disease or for other reasons such as theuse of systemic immunosuppressants

Study Design

Total Participants: 6
Treatment Group(s): 2
Primary Treatment: XSTEM-VLU
Phase: 1/2
Study Start date:
October 26, 2022
Estimated Completion Date:
October 31, 2025

Connect with a study center

  • Clinical Trial Center (CTC)

    Gothenburg, SE-413 46
    Sweden

    Active - Recruiting

  • Burn Centre, Linköping University Hospital

    Linköping, SE-581 85
    Sweden

    Site Not Available

  • Clinical Research Unit

    Lund, SE-221 85
    Sweden

    Site Not Available

  • Clinical Trial Consultants (CTC) Karolinska

    Stockholm, SE-171 64
    Sweden

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.